CLOs on the Move

PuraCap

www.puracap.com

 
EpiCeram® Controlled Release Skin Barrier Emulsion is a leading prescription product that has the ability to help repair and heal the skin barrier through a unique mode-of-action different from other medications and eczema treatments. Only EpiCeram® co...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Detroit Wayne Mental Health Authority

DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.

TBS Dental

We create premium products to make dentistry more efficient. Over the years, TBS has designed and developed a number of contemporary, state-of-the-art instruments with the intent of modernization.

Intersciences Inc

Intersciences Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation`s leading ophthalmology outsourcing facility and pharmaceutical compounding business.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.